Clinical Report: Dr. Peter Maslak Joins Roswell Park as Vice Chair of Clinical Affairs

Overview

Dr. Peter Maslak, a hematologic oncologist with over 25 years of expertise in clinical flow cytometry and immunophenotyping, has joined Roswell Park as Vice Chair of Clinical Affairs and Director of Flow Cytometry. His role will focus on advancing immune monitoring and cellular therapies, including CAR T-cell programs and transplant services.

Background

Flow cytometry and immune monitoring are critical in understanding and optimizing cancer therapies, particularly in hematologic malignancies. Dr. Maslak brings extensive experience from Memorial Sloan Kettering Cancer Center, where he contributed to cancer diagnosis, immunology, and transplant support. Roswell Park has a historic reputation in flow cytometry, positioning it well to expand its cellular therapy programs. The integration of immune monitoring supports personalized treatment approaches by assessing patient-specific immune responses.

Data Highlights

Dr. Maslak has over 25 years of experience in clinical flow cytometry and immunophenotyping. He has held multiple roles at Memorial Sloan Kettering Cancer Center over 35 years, including hematologist-oncologist and pathology department member. Roswell Park aims to expand its CAR T-cell and transplant programs with enhanced immune monitoring capabilities under his leadership.

Key Findings

• Dr. Maslak appointed Vice Chair of Clinical Affairs and Director of Flow Cytometry at Roswell Park.
• He has a 25+ year background in clinical flow cytometry and immunophenotyping, specializing in hematologic malignancies.
• His expertise supports the expansion of CAR T-cell therapy and transplant immune monitoring programs at Roswell Park.
• Immune monitoring enables assessment of treatment efficacy and patient-specific immune responses, facilitating personalized therapy.
• Roswell Park’s flow cytometry lab has a historic legacy and is positioned to achieve national and international recognition under Dr. Maslak’s leadership.
• Collaboration with scientists and clinicians is central to advancing research and clinical care through shared resources.

Clinical Implications

The integration of advanced immune monitoring and flow cytometry at Roswell Park will enhance the ability to tailor cellular therapies such as CAR T-cell treatments to individual patients. This personalized approach may improve outcomes by optimizing therapy selection based on immune response profiles. Clinicians should anticipate expanded diagnostic and monitoring capabilities that support precision oncology in hematologic cancers.

Conclusion

Dr. Peter Maslak’s appointment marks a strategic advancement for Roswell Park’s clinical and research programs in hematologic oncology. His leadership in flow cytometry and immune monitoring will drive innovation in cellular therapies and personalized cancer care.

References

1. Roswell Park Comprehensive Cancer Center 2024 -- Roswell Park Welcomes New Vice Chair of Clinical Affairs: Dr. Peter Maslak